Unprecedented Growth Opportunity BIOTECHNOLOGY

Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?  Contact in India

India - An Introduction  Population  States/UTs  Geographical Area  Languages recognised  Business language  Per Capita Income**  GDP** Over 1 bn mn sq kms 22 English US$ 534 US$ 650 bn **(at factor cost & at current prices) 1USD=43.54 INR (as on July 4, 2005) Source:CSO Statistics

India - Fast pace Growth  Largest democracy  4th largest economy by PPP index  6th largest energy consumer  ForEx reserves skyrocket from US$ 42 bn (2001) to US$ 133 bn (February, 2005)  GDP growth to continue between 6-8%  3rd largest economy by 2050: Goldman Sachs  Leading in IT & BPO  Oil & Gas and Biotechnology sunrise industries

India - Leading the world  Hero Honda - largest manufacturer of motorcycles  Moser Baer - 3rd largest optical media manufacturer in world  Pharmaceutical Industry - 4th largest in world  Walmart, GAP, Hilfiger sources more than USD 1bn worth apparel from India  100 Fortune 500 have set R&D facilities in India including GE, Delphi, Eli Lilly, HP, Heinz and Daimler Chrysler

Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?  Contact in India

Biotech Market - Dynamic and growing  Size ( ) US$ mn  Largest segment Biopharma  Revenue from exports ( ) 56%  Total investment( ) US$ 137 million Rate of growth over %

Bio Agri 6.95% Bio Pharma % Bio Services 8.95% Bio-IT 2.09 % Biopharma leads the way Composition of Indian Biotech Sector ( ) Bio Industrial 6.74% Source:Biospectrum-ABLE Survey

Market - A consistent uptrend % growth in investment 70% growth in employment 74% growth in R&D manpower 10% of global industry 1 million skilled jobs US$ 5 billion annual revenues Source: Confederation of Indian Industry (CII)

Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?  Contact in India

Indian Players

MNCs Scripting Success in India

Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?  Contact in India

Investments Annual investments in this sector will be of the order of US$ 150 mn and are growing at the rate of 25%. An additional investment of US$ 216 mn is expected in FY2005

 VaccineSales of US$ mn ( )  Therapeutic Marketing licenses granted for over 25 recombinant therapeutic proteins  Diagnostics Sales market - US$ mn ( ) Invest in Biopharmaceuticals

India: The Vaccine Hub Indian firms estimated to supply 90% of global demand for the measles vaccine, in the near future. Serum Institute, Pune is believed to be the world`s largest manufacturer of DPT vaccines. Indian Immunologicals operates the world`s second largest plant for veterinary vaccines and is also the world`s largest manufacturer of the vaccine against Foot and Mouth Disease.

Invest in Biopharmaceuticals  Therapeutic Accounts for 14% of total biopharma sales ( )  Diagnostics Forecast to grow by 35-40% in 2005 Immuno diagnostic market to increase 4 to 5 folds by 2005

Invest in Bioinformatics By 2006 bionformatics market to grow US$ 22.9 mn By 2006 US$ 120 mn Source: International Data Corporation (IDC) Opportunities for investment  Data mining  Gene annotation  Software bioinformatics interface development

 Genomics  Industrial Biotech Invest in Genomics and Industrial Biotech  Size ( ) US$ 73.5 mn

Invest in Agri Biotech Biofertilisers GM Crops and seeds Biopesticides Biofuels

Invest in Agri Biotech Biofertilisers GM Crops and seeds Biopesticides Biofuels

Quality Speed Technology Disease Profile Investigators Genetic diversity Ethics Quality guidelines conformed Patient enrolment rates upto six times higher than US CROs to benefit from India’s IT strengths in data management High incidence of infectious/lifestyle diseases Excellent pool of qualified & trained doctors and physicians           Clinical Trials - Destination India

Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?  Contact in India

The India Advantage Trained manpower and knowledge base Rich biodiversity Extensive clinical trials opportunities Excellent network of research laboratories Well-developed base industries

 40 National Research Institutes  300 life sciences colleges  120 medical colleges  200 biotech companies  100 teaching hospitals The Infrastructure Advantage 15,000 scientists 500,000 graduates per annum 17,500 medical graduates per annum Employing 25,000 scientists in R&D Employing medical & paramedical professionals

The R & D Advantage Genetic Engineering DNA technologies New Drug Delivery Systems Rational drug design Stem cell research Bioinformatics Biotech R&D strengths spread across range of segments

The Policy Advantage  India has transitioned from a process patent regime to a product patent regime w.e.f January, 2005  150% weighted deduction on R&D expenditure  Single window application processing proposed by DBT  New biotech proposals to be cleared within 150 days  Formation of a SME Growth Fund to provide equity support to small & medium units in the biotechnology sectors (Union Budget )

Union Budget  Benefits enjoyed by Export Oriented Units (EOU) extended to Biotech Parks - 100% FDI permitted through automatic route - BTP units exempt from payment of Income Tax - Export proceeds to be realised within 12 months - BTPs allowed to retain 100% export earnings in the EEFC account The Biotech Park Advantage

Biotechnology  India - An Overview  Market and Growth Potential  Players  Opportunities  Why India?  Contact in India

Contact in India Confederation of Indian Industry (CII) 23 Institutional Area Lodi Road New Delhi Tel Fax /